Your session is about to expire
← Back to Search
LY3819469 for Renal Function
Study Summary
This trial looks at the effects of a drug called LY3819469 on people with and without kidney problems. It'll assess safety, levels in the bloodstream, and how long it takes to get rid of. Trial length up to 17 weeks.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Media Library
- Your body mass index is between 19.0 and 42.0 kilograms per meter squared (kg/m²).You have a history of a health condition or have a current health condition.Your hemoglobin levels are lower than 8 grams per deciliter and you have significant symptoms of anemia.You are allergic to LY3819469 or similar substances, or have a history of significant allergies.You have taken part in a specific type of clinical trial for Lp(a) siRNA therapy in the past year.You have any unusual results in your 12-lead electrocardiogram (ECG).Your kidney function, measured by eGFR, is greater than or equal to 90 mL/min.You have severe kidney problems with an eGFR (a measure of kidney function) of less than 30 mL/min and you don't need dialysis.You have been receiving hemodialysis treatment regularly for at least 3 months before the study starts.Your body mass index is between 19.0 and 42.0 kilograms per square meter.
- Group 1: LY3819469 (Control)
- Group 2: LY3819469 (Severe Renal Impairment)
- Group 3: LY3819469 (End-Stage Renal Disease)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is enrollment in this research project still open?
"Based on the clinicaltrials.gov data, this medical trial is no longer enrolling patients. It was initially posted on April 25th 2023 and its last update came a day prior to that date. Nevertheless, there are 954 other trials currently accepting participants at the moment."
Is this trial open to participants under the age of 25?
"This trial's eligibility criteria require that all participants are between 18 to 85 years old. For those below and above this range, there are 62 trials for minors and 510 studies specifically targeting seniors."
Has FDA clearance been granted for LY3819469 (Control)?
"Our safety rating for the control drug LY3819469 is 1 due to its Phase 1 status, which means there are limited data affirming both its efficacy and security."
Who meets the qualifications for enrollment in this experiment?
"This medical trial is open to patients aged 18-85 with kidney failure. Currently, 28 individuals are being sought after for enrollment."
Who else is applying?
What state do they live in?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger